130 related articles for article (PubMed ID: 38437799)
21. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.
Gawor M; Holcman K; Franaszczyk M; Lipowska M; Michałek P; Teresińska A; Bilińska ZT; Rubiś P; Kostkiewicz M; Szot W; Podolec P; Grzybowski J
Cardiol J; 2022; 29(6):985-993. PubMed ID: 32789836
[TBL] [Abstract][Full Text] [Related]
23. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
24. Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype.
Sekijima Y; Campos RI; Hammarström P; Nilsson KP; Yoshinaga T; Nagamatsu K; Yazaki M; Kametani F; Ikeda S
J Peripher Nerv Syst; 2015 Dec; 20(4):372-9. PubMed ID: 26306725
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in transthyretin amyloidosis therapy.
Ueda M; Ando Y
Transl Neurodegener; 2014; 3():19. PubMed ID: 25228988
[TBL] [Abstract][Full Text] [Related]
26. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202304. PubMed ID: 37928601
[No Abstract] [Full Text] [Related]
27. Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran.
Di Stefano V; Fava A; Gentile L; Guaraldi P; Leonardi L; Poli L; Tagliapietra M; Vastola M; Fanara S; Ferrero B; Giorgi M; Perfetto F; Russo M; Russo D
Pharmgenomics Pers Med; 2022; 15():499-514. PubMed ID: 35592550
[TBL] [Abstract][Full Text] [Related]
28. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
29. A case of cardiac amyloidosis in an elderly Japanese patient with amyloidogenic transthyretin Val122Ile variant.
Ono R; Takahashi H; Sato T; Yamazaki T; Hori Y; Fukushima K
J Cardiol Cases; 2020 Nov; 22(5):221-225. PubMed ID: 33133314
[TBL] [Abstract][Full Text] [Related]
30. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
31. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
32. Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.
Cioffi CL; Raja A; Muthuraman P; Jayaraman A; Jayakumar S; Varadi A; Racz B; Petrukhin K
J Med Chem; 2021 Jul; 64(13):9010-9041. PubMed ID: 34138572
[TBL] [Abstract][Full Text] [Related]
33. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
[TBL] [Abstract][Full Text] [Related]
34. EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates.
Zou H; Zhou S
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762449
[TBL] [Abstract][Full Text] [Related]
35. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and therapeutic approaches to transthyretin amyloidosis.
Ando Y; Ueda M
Curr Med Chem; 2012; 19(15):2312-23. PubMed ID: 22471980
[TBL] [Abstract][Full Text] [Related]
37. Rare c.302C>T
Žebrauskienė D; Sadauskienė E; Masiulienė R; Aidietienė S; Šiaudinienė A; Pečeliūnas V; Žukauskaitė G; Žurauskas E; Valevičienė N; Barysienė J; Preikšaitienė E
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399526
[No Abstract] [Full Text] [Related]
38. Unusual presentation of rare
Gupta R; Lin M; Bokhari S
Future Cardiol; 2022 Jun; 18(6):471-476. PubMed ID: 35549533
[TBL] [Abstract][Full Text] [Related]
39. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
40. Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease.
Fenoglio R; Baldovino S; Barreca A; Bottasso E; Sciascia S; Sbaiz L; Papotti M; Roccatello D
Nephron; 2022; 146(5):481-488. PubMed ID: 35307708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
